CAR-T Archives

News and Trends 9 Dec 2019

Autolus Reveals Early Clinical Data of Next-Gen CAR-T Therapy

London-based Autolus has shown its next-generation CAR T-cell therapy does not induce some of the severe side effects that have led to deaths in patients treated with CAR T-cell treatments currently on the market. Since their arrival on the market in 2017, CAR T-cell therapies have provided hope to patients with rare forms of blood […]

December 9, 2019 - 4 minutesmins - By Clara Rodríguez Fernández

News and Trends 14 Nov 2019

Cellectis’ Off-the-Shelf CAR T-Cell Therapy Shows Solid Tumor Potential

An off-the-shelf, gene edited CAR T-cell therapy, developed by the French biotech Cellectis, could be used to tackle solid tumors, which have so far been beyond the reach of other CAR T-cell therapies. The approved CAR T-cell therapies Kymriah and Yescarta contain genetically modified immune T-cells that can fight certain types of blood cancer. However, […]

November 14, 2019 - 2 minutesmins - By Jonathan Smith

News and Trends 12 Nov 2019

First Results Out for Off-the-Shelf CAR-T Therapy in Solid Tumors

The Belgian company Celyad has released the first interim clinical efficacy data for an off-the-shelf CAR T-cell immunotherapy in solid tumors. The interim results come from an ongoing phase I trial in patients with colorectal cancer. Of the 12 patients given Celyad’s CAR T-cell immunotherapy so far, six have seen their tumors shrink. The therapy […]

November 12, 2019 - 2 minutesmins - By Jonathan Smith

lightcast discovery cell therapy cambridge uk

Startup Scout 27 Sep 2019

This Biotech Can Screen CAR T-Cells Using Only Light and Microfluidics

Based in Cambridge, UK, Lightcast Discovery is developing microfluidics technology that automates cell screening experiments by using lasers. Mission: To automate cell screening experiments, such as those used when screening CAR T-cell immunotherapies. This would let companies test therapies in complex cell experiments, such as cell-to-cell interactions, which are difficult with traditional drug-screening tools. Cell […]

September 27, 2019 - 3 minutesmins - By Jonathan Smith

News and Trends 12 Aug 2019

Manufacturing Delays Set Back Autolus’ CAR-T Programs by Five Months

The UK biotech Autolus’ shares have slumped as construction delays from a new manufacturing site have pushed back its CAR-T cell immunotherapy programs. Autolus is developing treatments for blood cancer that involve engineering patients’ own immune cells to kill cancer cells, known as autologous CAR-T cell immunotherapies. Earlier this year, Autolus licensed a new manufacturing […]

August 12, 2019 - 2 minutesmins - By Jonathan Smith

In Depth 11 Jun 2019

Gamma Delta T Cells: A New Hope Against Cancer

A new wave of therapies based on a unique type of immune cells, called gamma delta T cells, has the potential to treat cancer with stronger responses and fewer side effects. Immunotherapies based on T cells are becoming a huge trend in the treatment of cancer, especially CAR-T cells. These genetically-modified T cells have shown […]

June 11, 2019 - 5 minutesmins - By Clara Rodríguez Fernández

News and Trends 5 Jun 2019

Highlights from European Biotech at ASCO 2019

European biotech companies gathered in Chicago, USA, to share the latest advances in cancer research at the biggest cancer conference of the year, ASCO 2019. This year’s conference has drawn fewer big blockbuster headlines than other years, but there was plenty to see nonetheless. There were results from many different clinical trials by big pharma […]

June 5, 2019 - 5 minutesmins - By Jonathan Smith

News and Trends 3 Jun 2019

Belgian and US Biotechs Team up to Reduce CAR T Side Effects

The diagnostics company Biocartis is collaborating with Kite Pharma to monitor the progress of CAR T-cell therapies in patients to better manage side effects. CAR T-cell therapies have revolutionized the way we treat cancer. Instead of giving the patient a classical drug, companies can inject them with living, genetically engineered cells that kill cancer cells. […]

June 3, 2019 - 3 minutesmins - By Jonathan Smith

News and Trends 1 May 2019

Next-Generation CAR-T Therapy Shows Promise in Child’s Neuroblastoma

Cell Medica’s next-generation CAR-T cell therapy has resulted in ‘extensive tumor regression’ in a child with high-risk neuroblastoma, one of the deadliest types of childhood cancer. Only available to cancer patients for the last couple of years, CAR-T cell therapy has had impressive results in treating patients for whom other available options do […]

May 1, 2019 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 27 Feb 2019

UK Biotech Gets Huge Grant to Launch Off-the-Shelf CAR-T Cancer Therapy to Clinic

The UK biotech Cell Medica has received a €7.6M ($8.7M) grant from the Cancer Prevention and Research Institute of Texas to advance an off-the-shelf CAR-T cell therapy that can work not only in blood cancer but also in solid tumors. The funding will help the company to develop a special type of CAR-T cell therapy […]

February 27, 2019 - 3 minutesmins - By Jonathan Smith

Best in Biotech 31 Dec 2018

European Biotech’s Biggest News of 2018

With this year coming to a close, it’s now time to look back at the biggest biotech news stories of 2018 in Europe, which include CRISPR-Cas9 controversy, big financial deals, and spider silk airplanes. The year 2018 brought a lot of change to the biotech industry in Europe, with clinical trials, approvals and Brexit […]

December 31, 2018 - 12 minutesmins - By Jonathan Smith

Best in Biotech 24 Dec 2018

Looking Back on 2018: Our 10 Most Popular Interviews

As 2018 draws to a close and our thoughts are torn between holiday plans and what the new year may bring, we decided to look back and revisit the people and the stories that attracted our readers the most during the year. These were well received the first time around, so we thought you might […]

December 24, 2018 - 8 minutesmins - By Helen Albert

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us